Androgen deprivation therapy does not keep localized prostate
cancer from spreading, new study says
February 27, 2006
Laptop Battery Hormonal treatment gaining popularity for localized prostate
cancer despite little understanding of its effectiveness
The fear of having prostate cancer can be devastating to most men. Prostate cancer is most successfully treated when discovered early. Nearly 80 percent of all prostate cancers is discovered while they are still localized, or confined to the prostate. year survival rate for men diagnosed with prostate tumors that are discovered at this early stage is a whopping 100 percent. Testing works!
Thinkpad SAN FRANCISCO - Oregon Health & Science University Cancer
Institute researchers wanted to know if depriving men of
testosterone actually keeps cancer from spreading beyond the
prostate. What they found is that men who have localized prostate
cancer with certain high-risk features and receive this treatment -
known as androgen deprivation therapy - remain at risk of dying
from prostate cancer.
For information on cancer that has come back or spread to other parts of the body, see the topic Prostate Cancer, Advanced or Metastatic.
Microsoft "The notion that androgen deprivation therapy will hold prostate
cancer at bay while you die of something else is not proving to be
entirely true," said Tomasz Beer, M.D., director of the Prostate
Cancer Research Program in the Oregon Health & Science
University Cancer Institute.
And, the news about aspirin just keeps getting better. In a study published in the Dec. 9 Journal of Biological Chemistry, inducing ligand (TRAIL) destruct. The investigators say that if these findings hold up in larger studies, aspirin could become a routine therapy for helping to prevent the recurrence of many aggressive cancers, such as prostate and colon cancers.
Laptop Computers This is especially important because recent studies of physician
practice trends show that androgen deprivation therapy is being
used with increased frequency for men with prostate cancer that has
not spread.
4) Of the 749 men diagnosed with prostate cancer in the study, fully 58% of the diagnosed prostate cancers occurred during the second year of the trial.
Laptop Computer "Reasons for this trend are not really known, but may include a
desire to do something rather than do nothing on the part of both
physicians and patients," Beer said. "Unfortunately, these men may
be enduring significant side effects for an uncertain benefit."
Prostate cancer is the fourth most common cancer in men worldwide. It is the most common cancer and the second leading cause of cancer death in men in the United States. Conventional treatments for prostate cancer include surgery, radiation therapy, and medications that alter hormone activity. Sexual function is impaired in most men after each of these therapies. Other major side effects include urinary incontinence following surgery, fecal incontinence following radiation, and hormonal problems such as breast swelling and pain, hot flushes, and osteoporosis during medication therapy.
Desktop Computer Androgen deprivation therapy, also known as hormone therapy, is
the gold standard of care for men whose prostate cancer is advanced
and has spread throughout the body. The therapy works by shutting
down male hormones, principally testosterone, that can promote
prostate cancer growth. This common treatment for prostate cancer
wipes out most male hormones found in the body. Side effects can be
significant and include erectile dysfunction, hot flashes, fatigue,
osteoporosis, high cholesterol, anemia, forgetfulness and
insomnia.
Notebooks Little is known about the effectiveness of hormonal therapy in
men whose cancer remains localized within the prostate, so Beer and
his colleagues decided to study data from the Prostate Cancer
Outcome Study (PCOS). They presented their results on Saturday,
Feb. 25, at the Prostate Cancer Symposium in San Francisco.
Lenovo In the retrospective study, the research team examined
demographic data, socio-economic factors and tumor biology in
relationship to overall survival and cancer-specific survival for a
subgroup of 276 PCOS subjects who had localized prostate cancer and
received androgen deprivation therapy as their primary treatment.
Between 1994 and 1995, a total of 3,486 men were enrolled in PCOS
within six months of prostate cancer diagnosis.
Hard Drive The analysis showed that out all the demographic and
socio-economic factors considered, overall survival was predicted
only by age and certain features of prostate cancer. Tumor biology,
which is measured by Gleason score, was the only independent
predictor of cancer specific survival. Tumor mass as measured by
PSA approached statistical significance as a predictor. Nearly 10
percent of men died from prostate cancer within 5 years of starting
hormonal therapy.
Travelstar "Our study indicates that cancer remains an important
contributor to overall mortality in these men, particularly those
with high Gleason score and high serum PSA," Beer said. "These data
will be useful for men with localized prostate cancer choosing
between aggressive treatments such as surgery or radiation,
observation and androgen deprivation therapy."
Gateway In an earlier OHSU Cancer Institute study of the effectiveness
of hormone deprivation as a primary therapy for localized prostate
cancer, researchers found that younger men and those with
higher-grade tumors are more likely to experience disease
progression during treatment. They also found that men with
localized prostate cancer on hormone therapy experience a higher
than expected rate of bone fractures caused primarily by
treatment-related osteoporosis.
Laptop Parts "Studies suggest that more needs to be known about the risks and
benefits of this treatment before we recommend it to patients with
localized disease," Beer said.
Software Prostate cancer is the most common cancer in men and the second
leading cause of cancer-related death in American men. Overall, 1
in 6 men will develop prostate cancer during his lifetime.
Hard Drives Oregon Health & Science University
[ Comment, Edit or Article Submission ]
